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1. INTRODUCTION {#ajmgb32639-sec-0001}
===============

The Kraepelinian dichotomy, which postulates adult affective and psychotic disorders to be separate categorical entities, still has a major influence on Western psychiatry. It therefore remains in current diagnostic systems such as the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5). This dichotomous view has recently been questioned by biological research (O\'Donovan & Owen, [2016](#ajmgb32639-bib-0046){ref-type="ref"}). In addition, there is extensive overlap of symptoms between schizophrenia (SZ) and bipolar disorder (BD) as observed in clinical day‐to‐day reality (Murray et al., [2004](#ajmgb32639-bib-0043){ref-type="ref"}). Traditional categorical nosological systems have therefore been fundamentally challenged during the past years. Alternative concepts of hierarchically and dimensionally measured phenotypes have been put forward by the NIMH Research Domain Criteria (RDoC; Cuthbert & Insel, [2010](#ajmgb32639-bib-0015){ref-type="ref"}; Insel et al., [2010](#ajmgb32639-bib-0030){ref-type="ref"}) and the Hierarchical Taxonomy of Psychopathology (HiTOP; Kotov et al., [2017](#ajmgb32639-bib-0035){ref-type="ref"}), the former emphasizing the need for biologically informed domains early on. To this end, genetics have often played an important role in redefining psychiatric diagnoses (Robins & Guze, [1970](#ajmgb32639-bib-0053){ref-type="ref"}). More recently, findings regarding an overlapping but distinct genetic basis of SZ and BD in both family (Lichtenstein et al., [2009](#ajmgb32639-bib-0039){ref-type="ref"}) and molecular genetic studies (Cross‐Disorder Group of the Psychiatric Genomics Consortium, [2013](#ajmgb32639-bib-0014){ref-type="ref"}; Forstner et al., [2017](#ajmgb32639-bib-0020){ref-type="ref"}; Purcell et al., [2009](#ajmgb32639-bib-0050){ref-type="ref"}), have accelerated the momentum toward dimensionally defined diagnosis (Craddock & Owen, [2010](#ajmgb32639-bib-0013){ref-type="ref"}) of severe mental disorders. Even though spectrum phenotypes have been introduced in the DSM‐5 in the areas of autism and substance use, this modern diagnostic approach has not been applied to SZ and BD. However, as outlined above, there are several compelling reasons for the introduction of a psychosis spectrum disorder (for a detailed discussion see Guloksuz & van Os, [2017](#ajmgb32639-bib-0025){ref-type="ref"}). There is thus a pressing need to incorporate this biological information into future diagnostic systems.

Against this background, addressing two important issues might pave the way for a successful research into this matter: First, longitudinal research is necessary to capture variation over time. Pronounced heterogeneity in the longitudinal course of both SZ (e.g., Carpenter & Kirkpatrick, [1988](#ajmgb32639-bib-0011){ref-type="ref"}; Heilbronner, Samara, Leucht, Falkai, & Schulze, [2016](#ajmgb32639-bib-0027){ref-type="ref"}) and BD (e.g., Angst, [1978](#ajmgb32639-bib-0007){ref-type="ref"}) exists. Overlap of symptoms, comorbidity and instability of diagnoses over time occur frequently in everyday clinical practice. Thus, just as subtypes of traditionally defined nosological categories emerged by examining their clinical course (e.g., Bleuler, [1968](#ajmgb32639-bib-0010){ref-type="ref"}), similarities and differences between traditionally defined SZ and BD may emerge when a combination of biological information and clinical course is considered. While only few modern longitudinal studies of severe mental illnesses exist, the longitudinal course of affective disorders, such as BD, has received particularly little attention to date (Pfennig et al., [2017](#ajmgb32639-bib-0049){ref-type="ref"}). Second, a major emphasis on phenomics is needed, "the systematic study of phenotypes on a genome‐wide scale" (Bilder et al., [2009](#ajmgb32639-bib-0009){ref-type="ref"}). In an age in which genomic and other high‐throughput data can be obtained relatively inexpensively and rapidly, a major challenge is to obtain extensive high‐quality phenotype data. Such data are required to establish meaningful genotype--phenotype relationships, and will ultimately lead to biologically informed patient stratification (Kapur, Phillips, & Insel, [2012](#ajmgb32639-bib-0032){ref-type="ref"}).

The aim of this communication is to introduce the PsyCourse study, a longitudinal study of severe mental disorders on the affective‐to‐psychotic continuum, which aims to address these issues. Deep phenotyping is combined with an extensive collection of biological material at every measurement point, enabling the combination of multilevel omics and longitudinal clinical data. Specifically, current symptomatology, cognitive status, and self‐report measures are assessed at every measurement point, interspersed with the collection of relevant cross‐sectional data (see Supporting Information Table [1](#ajmgb32639-supitem-0002){ref-type="supplementary-material"}).

Here, we provide an initial characterization of the PsyCourse study sample. First, we present longitudinal data on positive, depressive, and manic symptoms as well as data on global psychosocial functioning of the clinical participants of the PsyCourse study. We compare these variables between two broad diagnostic groups within the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM‐IV) framework, defined as psychotic and affective, by their predominant symptoms. In addition, as proof of principle of the PsyCourse sample\'s potential for genomic analyses, we use polygenic risk scores (PRS) for SZ (SZ‐PRS) for a first biological characterization of these diagnostic groups. PRS are a method for estimation of the polygenic load of common risk alleles an individual carries for a certain trait or disorder (Purcell et al., [2009](#ajmgb32639-bib-0050){ref-type="ref"}); for overview see Wray et al. ([2014](#ajmgb32639-bib-0063){ref-type="ref"}; in this case for SZ). Findings from PRS analyses support the notion of both overlapping (Purcell et al., [2009](#ajmgb32639-bib-0050){ref-type="ref"}) and specific (Ruderfer et al., [2014](#ajmgb32639-bib-0054){ref-type="ref"}) genetic backgrounds of SZ and BD as well as the continuum model of psychosis (Tesli et al., [2014](#ajmgb32639-bib-0058){ref-type="ref"}). To study genetic overlap between disorders by means of PRS, it is usually analyzed whether PRS for one disorder, for example, SZ, can successfully predict case--control status for other traits, for example BD (Cross‐Disorder Group of the Psychiatric Genomics Consortium, [2013](#ajmgb32639-bib-0014){ref-type="ref"}; Purcell et al., [2009](#ajmgb32639-bib-0050){ref-type="ref"}). Another approach, focusing on the specific genetic backgrounds of SZ and BD, was used by Ruderfer et al. ([2014](#ajmgb32639-bib-0054){ref-type="ref"}) who created a PRS for the discrimination between SZ and BD. Here, we used SZ‐PRS because the available discovery genome‐wide association study (GWAS) comparing SZ patients and controls is based on a substantially larger sample (*N* = 36,989 patients vs. *N* = 113,075 controls; Ripke et al., [2014](#ajmgb32639-bib-0052){ref-type="ref"}) than the largest published GWAS comparing BD and controls (*N* = 13,902 patients vs. *N* = 19,279 controls; Charney et al., [2017](#ajmgb32639-bib-0012){ref-type="ref"}). Unlike the studies described above, we directly explore to what extent SZ‐PRS can differentiate between two groups of patients in the PsyCourse study, predominantly psychotic and affective participants. As longitudinal research inevitably leads to attrition, selective dropout of subgroups of study participants is a major challenge. This is especially important as it is well‐known that demographic variables like age, sex, socioeconomic status as well as emotional and behavioral problems are associated with attrition (de Graaf, van Dorsselaer, Tuithof, & ten Have, [2013](#ajmgb32639-bib-0016){ref-type="ref"}; Wolke et al., [2009](#ajmgb32639-bib-0062){ref-type="ref"}). Notably, a recent study found higher SZ‐PRS to be associated with nonparticipation over time in a population‐based cohort study (Martin et al., [2016](#ajmgb32639-bib-0041){ref-type="ref"}). Therefore, we also present analyses on possible demographic and illness‐related predictors of dropout and further explore the association of SZ‐PRS and dropout in our patient sample. A selective dropout of participants with a specific biological profile would have important implications for longitudinal biological research in psychiatry.

2. MATERIALS AND METHODS {#ajmgb32639-sec-0002}
========================

2.1. Properties of the PsyCourse study {#ajmgb32639-sec-0003}
--------------------------------------

PsyCourse is an ongoing multicenter study, conducted by a network of clinical sites in Germany and Austria. At the time of writing, 18 different clinical centers participated in data collection of clinical participants, two of which additionally collect data from nonclinical (control) individuals. The study protocol was approved by the respective ethics committee for each study center and was carried out following the rules of the Declaration of Helsinki of 1975, revised in 2008. Initially, the project was approved by the Ethics Committee of the University Medical Center Goettingen. Some clinical centers were teaching hospitals of the University Medical Center Goettingen, and were thus covered by this initial approval. For those clinical sites that were not covered, we obtained additional approval from the respective Ethics Committees. For all centers, these were (clinical centers in parentheses): Ethics Committees of the University Medical Center Goettingen (UMG Goettingen, Bad Zwischenahn, Eschwege, Asklepios Specialized Hospital Goettingen, Hildesheim, Lüneburg, Liebenburg, Osnabrück, Rotenburg, Tiefenbrunn, Wilhemshaven), Medical Faculty of the LMU Munich (Munich and Augsburg), Medical Faculty of the RU Bochum (Bochum), Medical Association Bremen (Bremen Ost), Medical University of Graz (Graz), Ulm University (Günzburg) and Medical Association Westfalen‐Lippe and Medical Faculty University of Münster (Münster).

Study participants are assessed at four points in time, in intervals of 6 months, hereafter referred to as study visits 1 (T1; baseline), 2 (T2; +6 months), 3 (T3; +12 months), and 4 (T4; +18 months). Additional visits should be conducted for clinical participants if they are readmitted for inpatient treatment during the study period. Importantly, participating individuals are allowed to miss one or more follow‐up study visits without being excluded from the study. At each study visit, venous blood samples are collected, permitting extraction of biomaterials such as DNA, RNA, plasma, and serum. In addition, a comprehensive set of phenotype data is collected, assessing symptom dimensions, cognitive function, and self‐report measures (Supporting Information Table [1](#ajmgb32639-supitem-0002){ref-type="supplementary-material"}; Altman, Hedeker, Peterson, & Davis, [1997](#ajmgb32639-bib-0002){ref-type="ref"}; American Psychiatric Association, [2002](#ajmgb32639-bib-0003){ref-type="ref"}; Angermeyer, Kilian, & Matschinger, [2000](#ajmgb32639-bib-0006){ref-type="ref"}; Army Individual Test Battery, [1944](#ajmgb32639-bib-1008){ref-type="ref"}; Aster, Neubauer & Horn, [2006](#ajmgb32639-bib-2008){ref-type="ref"}; McGuffin, Farmer, & Harvey, [1991](#ajmgb32639-bib-0042){ref-type="ref"}; Grabe et al., [2012](#ajmgb32639-bib-0023){ref-type="ref"}; Grof et al., [2002](#ajmgb32639-bib-0024){ref-type="ref"}; Hautzinger, Keller, & Kühner, [2006](#ajmgb32639-bib-0026){ref-type="ref"}; Helmstaedter, Lendt, & Lux, [2001](#ajmgb32639-bib-0028){ref-type="ref"}; Kay, Fiszbein, & Opler, [1987](#ajmgb32639-bib-0033){ref-type="ref"}; Konings, Bak, Hanssen, van Os, & Krabbendam, [2006](#ajmgb32639-bib-0034){ref-type="ref"}; Krüger, Bräunig, & Shugar, [1997](#ajmgb32639-bib-0036){ref-type="ref"}; Lehrl, [2005](#ajmgb32639-bib-0038){ref-type="ref"}; Margraf, [1994](#ajmgb32639-bib-0040){ref-type="ref"}; McGuffin, Farmer, & Harvey, [1991](#ajmgb32639-bib-0042){ref-type="ref"}; National Institute of Mental Health, [1976](#ajmgb32639-bib-0044){ref-type="ref"}; Norbeck, [1984](#ajmgb32639-bib-0045){ref-type="ref"}; Rammstedt & John, [2007](#ajmgb32639-bib-0051){ref-type="ref"}; Rush, Carmody, & Reimitz, [2000](#ajmgb32639-bib-0055){ref-type="ref"}; Stefanis et al., [2002](#ajmgb32639-bib-0057){ref-type="ref"}; Ware, Kosinski, & Keller, [1996](#ajmgb32639-bib-0059){ref-type="ref"}; Wittchen & Fydrich, [1997](#ajmgb32639-bib-0061){ref-type="ref"}; Young, Biggs, Ziegler, & Meyer, [1978](#ajmgb32639-bib-0064){ref-type="ref"}).

### 2.1.1. Clinical participants and broad diagnostic groups {#ajmgb32639-sec-0004}

Adult patients (≥18 years), with an ICD‐10 life‐time diagnosis of SZ (F20.x), brief psychotic disorder (F23.x), schizo‐affective disorder (SZA; F25.x), BD (F31.x), manic episode (F30.x), or recurrent major depression (reMDD; F33.x) are identified based on recommendations of the clinical staff or by querying patient registries of the participating clinical centers. Eligible individuals are invited to participate in the first study visit (T1), where, after giving informed consent (see below), their diagnosis is reassessed within the DSM‐IV framework using an adapted version of the Structured Clinical Interview for DSM‐IV; Axis I Disorders (SCID‐I; Wittchen & Fydrich, [1997](#ajmgb32639-bib-0061){ref-type="ref"}). Participants with a life‐time DSM‐IV diagnosis of SZ (295.10/295.20/295.30/295.60/295.90) or schizophreniform disorder (295.40), brief psychotic disorder (298.8), or SZA (295.70) constitute the group with predominantly psychotic symptoms, whereas those with a life‐time DSM‐IV diagnosis of BD (296.0x/296.4x/296.5x/296.6x/296.8x) or reMDD (296.3x) constitute the predominantly affective group. If none of the above DSM‐IV diagnoses can be ascertained, clinical participants are excluded from the study. Participants must be proficient in German language to enroll in the study.

### 2.1.2. Nonclinical (control) participants {#ajmgb32639-sec-0005}

Inhabitants of the catchment areas of Göttingen and Munich are contacted either by mail, based on address lists acquired from the local Residents' Registration Office, or by advertisements in public areas and are invited to participate in the study. Individuals must be proficient in German language to enroll in the study. Those included in the study follow a similar protocol as the clinical participants (see Supporting Information Table [1](#ajmgb32639-supitem-0002){ref-type="supplementary-material"}). History of affective or psychotic illness is assessed using a short diagnostic interview for mental disorders (Margraf, [1994](#ajmgb32639-bib-0040){ref-type="ref"}).

### 2.1.3. Broad informed consent {#ajmgb32639-sec-0006}

Before study participation, written informed consent is obtained from study participants. A special broad informed consent is required from participants, as the exact research objectives are not specified and both phenotypic data and biomaterial are to be stored until they are no longer useful for research (German National Ethics Council, [2004](#ajmgb32639-bib-0022){ref-type="ref"}). According to European and German law, such broad informed consent is only possible if special data protection measures are taken to shield personal data from unauthorized access (see Section [2.1.5](#ajmgb32639-sec-0008){ref-type="sec"} on data protection). Participating individuals must explicitly agree to these measures, if they want to participate in the study. In addition, potential participants must decide whether they want to be informed about possible incidental findings that the study may uncover. Collaboration with nonpsychiatric research disciplines and the possibility to jointly analyze data together with other researchers or research consortia is explicitly allowed, albeit only using pseudonymized data. Furthermore, participants are asked to release medical facilities involved in their prior treatment from doctor--patient confidentiality, so that information on their past medical records can be obtained. This serves as an additional source of information on their medical history.

### 2.1.4. Opt‐out {#ajmgb32639-sec-0007}

If a participant decides to opt‐out after enrolling in the study, two options exist: Disposal of the participant\'s biomaterial and permanent deletion of all phenotypic data, orAll information collected until that point in time will be retained but irreversibly anonymized.

Data that are already part of scientific analyses at the time of the opt‐out may be used further, regardless of the opt‐out, albeit only in anonymized form.

### 2.1.5. Data protection {#ajmgb32639-sec-0008}

As we collect sensitive phenotypic data and biomaterials, a data protection concept was developed (Demiroglu et al., [2012](#ajmgb32639-bib-0018){ref-type="ref"}). Briefly, it includes an array of organizational measures such as pseudonymization to minimize the risk of participant identification and unauthorized transmission of personal data to third parties. Four different IT components have been established by the Department of Medical Informatics at the University Medical Center, Göttingen, Germany (see Supporting Information Figure [1](#ajmgb32639-supitem-0001){ref-type="supplementary-material"}): The identity tool, responsible for storing the identifying data and for generating two different pseudonyms.The administrative tool, for managing study organization, informed consent, and communication with the study participants (linked to the identity tool).The phenotype database, containing information collected using rating scales, questionnaires, and cognitive tests.The biomaterial database for administering the collected biological samples.

### 2.1.6. Interviewers {#ajmgb32639-sec-0009}

Interviewers are provided with instructions in written form for all instruments and each new interviewer is extensively trained in administering the phenotyping battery by an experienced interviewer. Depending on interviewer experience, training includes discussing the instructions in detail, watching an experienced investigator conducting a visit and performing a visit under supervision of the latter. In addition, trainings for all investigators are held on a regular basis.

2.2. Biological‐psychiatric analyses in the PsyCourse resource {#ajmgb32639-sec-0010}
--------------------------------------------------------------

Clinical data presented herein are from a snapshot of the phenotype database taken on September 19th, 2016 and include a total of 891 clinical participants. Regarding biomaterial, venous blood samples were collected at each study visit. Briefly, DNA, RNA, and plasma and serum samples were prepared using standard methods. Data were analyzed using R ([www.r-project.org](http://www.r-project.org), version 3.3.2), and SPSS (IBM, version 24).

### 2.2.1. Phenotype analyses {#ajmgb32639-sec-0011}

Cross‐sectional phenotype data were analyzed with Pearson\'s chi‐squared and *t* tests, depending on the type of data (see Table [1](#ajmgb32639-tbl-0001){ref-type="table"}). Longitudinal data were analyzed using linear mixed‐effect regression (R package lme4; Bates, Maechler, Bolker, & Walker, [2014](#ajmgb32639-bib-0008){ref-type="ref"}). The variables age at first study visit, psychiatric treatment at first study visit (ordinal variable with levels "outpatient/no psychiatric treatment" and "in‐ or day patient"), sex, group, and time as well as interactions between sex, group, and time entered the model as fixed effects. Subject and clinical center of the first study visit were modeled as random intercept effects. To fulfill the requirement of normally distributed residuals, we transformed data of the inventory of depressive symptomatology (IDS‐C~30~), the young mania rating scale (YMRS) and the positive and negative syndrome scale (PANSS) positive score using the natural logarithm. Subsequent visual inspection of the residuals of each model did not show any obvious deviation from normality. The ANOVA function in the R lmerTest package (Kuznetsova, Brockhoff, & Christensen, [2016](#ajmgb32639-bib-0037){ref-type="ref"}) was used to obtain *p*‐values for fixed effects using Satterthwaite\'s approximation of degrees of freedom. *p*‐Values of the four linear mixed‐effect models were false discovery rate (FDR) corrected to account for Type‐I error cumulation resulting from multiple comparisons. A coefficient of determination (*R* ^2^) was calculated for each model with the R r2glmm package (<https://github.com/bcjaeger/r2glmm>) using the Nakagawa and Schielzeth ([2013](#ajmgb32639-bib-1044){ref-type="ref"}) method.

###### 

Comparisons between patient groups with predominantly affective versus predominantly psychotic disorders on demographic variables at the first study visit (T1)

                                                     Affective       Psychotic       Test statistic   DF       *P*
  -------------------------------------------------- --------------- --------------- ---------------- -------- --------
  Female sex, *n* (%)                                178 (48.5)      210 (40.1)      5.89 (χ^2^)      1        .015
  Age at first interview, mean (range)               45.4 (18--78)   40.8 (18--73)   5.27 (*t*)       741.43   \<.001
  Age at illness onset, mean (range)                 33.6 (11--73)   27.9 (7--73)    6.94 (*t*)       592.21   \<.001
  Marital status single (never married), *n* (%)     158 (43.1)      336 (64.1)      37.35 (χ^2^)     1        \<.001
  Family history of psychiatric illness, *n* (%)     268 (77.7)      334 (67.1)      10.73 (χ^2^)     1        .001
  In‐ or day patient at first study visit, *n* (%)   128 (34.9)      312 (59.5)      48.16 (χ^2^)     1        \<.001

DF = degrees of freedom.

### 2.2.2. Genotyping and imputation of genetic data {#ajmgb32639-sec-0012}

DNA samples of 825 clinical participants were genotyped using the Illumina Infinium PsychArray (Illumina), yielding information for approximately 590,000 genetic markers. More than 10% of these markers are in genetic loci previously associated with neuropsychiatric disorders. After standard quality control procedures, genotype imputation was performed using SHAPEIT2 (<https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html>) and IMPUTE2 (<http://mathgen.stats.ox.ac.uk/impute/impute_v2.html>; Andlauer et al., [2016](#ajmgb32639-bib-0005){ref-type="ref"}; Delaneau, Zagury, & Marchini, [2012](#ajmgb32639-bib-0017){ref-type="ref"}; Howie, Donnelly, & Marchini, [2009](#ajmgb32639-bib-0029){ref-type="ref"}). The 1000 Genomes project dataset (<http://www.internationalgenome.org/>; Phase 3 integrated variant set) was used as reference panel. Genetic variants with a poor imputation quality (INFO \<0.8) were not included in downstream analyses.

### 2.2.3. Genomic analysis of population structure {#ajmgb32639-sec-0013}

The EIGENSOFT package (smartPCA; Patterson, Price, & Reich, [2006](#ajmgb32639-bib-0048){ref-type="ref"}) was used to model ancestry differences between the study participants. It uses a principal component analysis based on a pruned subset of approximately 50,000 autosomal SNPs, after excluding regions with high linkage disequilibrium.

### 2.2.4. Polygenic risk scores {#ajmgb32639-sec-0014}

SZ‐PRS were calculated with PLINK 1.90 (<https://www.cog-genomics.org/plink/1.9>) using the imputed genotypes. Briefly, summary statistics from the SZ GWAS of the Psychiatric Genomics Consortium (<http://www.med.unc.edu/pgc>; Discovery Sample) were used to ascertain risk variants, their *p*‐values, and associated odds ratios (ORs; Ripke et al., [2014](#ajmgb32639-bib-0052){ref-type="ref"}). For this purpose a clumped training dataset of 102,636 independent SNPs available in the aforementioned website (Psychiatric Genomics Consortium) was used for SZ‐PRS calculations. Our imputed genotyped set had a substantial overlap with the training set (93,700 SNPs; 91.3% overlap). In the sample of the present study (Target Sample), the number of risk alleles carried by an individual (0, 1, or 2) for each SNP contributing to the PRS, was multiplied by the logarithm of the OR for that particular variant according to the results from the Discovery Sample. The resulting values were summed up in an additive fashion to obtain an estimate of the SZ genetic burden for each individual at 11 different *p*‐value thresholds (*p* ≤ 5\*10‐8; *p* ≤ .0001; *p* ≤ .001; *p* ≤ .01; *p* ≤ .05; *p* ≤ .1; *p* ≤ .2; *p* ≤ .3; *p* ≤ .4; *p* ≤ .5; *p* ≤ 1). SZ‐PRS do not significantly deviate from normality and were standardized using z‐score transformation. Since two phenotypes (diagnostic group, see Section [2.2.5](#ajmgb32639-sec-0015){ref-type="sec"}, and follow‐up study participation, see Section [2.2.6](#ajmgb32639-sec-0016){ref-type="sec"}) were tested for association with SZ‐PRS, all *p*‐values from these logistic regression models were FDR corrected to account for Type‐I error cumulation resulting from multiple comparisons.

### 2.2.5. Polygenic risk score analyses of diagnostic group {#ajmgb32639-sec-0015}

Ancestry principal components were calculated specifically for the subsample entering these analyses (for methods see Section [2.2.3](#ajmgb32639-sec-0013){ref-type="sec"}) to be able to correct for potential effects of population substructure. Blockwise logistic regression analyses were used to estimate the amount of variation of diagnostic group (predominantly affective versus psychotic symptoms) explained by z‐standardized SZ‐PRS at 11 different *p*‐value thresholds. Potential confounding variables, namely sex, age at baseline, age^2^, sex × age interaction as well as the first five ancestry principal components, were entered in the first block. In the second block, the predictor of interest, the respective z‐standardized SZ‐PRS, was added. The reported estimates of change in *R* ^2^ represent the gain in Nagelkerke\'s *R* ^2^ by adding SZ‐PRS to the model.

### 2.2.6. Analyses of follow‐up study participation {#ajmgb32639-sec-0016}

As described in Section [2.1](#ajmgb32639-sec-0003){ref-type="sec"}, study participants are allowed to miss one or more follow‐up study visits without being excluded from the study. To address the question of selective dropouts in the PsyCourse study, subjects with baseline data only, hereafter referred to as the dropout group, were compared to subjects with follow‐up data for at least one timepoint within the 18‐month study period, hereafter referred to as the follow‐up group. To assure a valid assignment to these groups in the ongoing project, the study period of 18 months plus an additional time of 5 months for data entry were considered. Since the export from the database was carried out on September 19th, 2016, only subjects with a T1 before October 19th, 2014 were selected for these analyses (*N* = 678).

Logistic regression (forced entry method) was used to test the effects of the following phenotypic predictors on group‐membership (dropout group vs. follow‐up group): sex, age at baseline, age2, age × sex interaction, center, diagnosis, educational status, psychiatric treatment at baseline, duration of illness, PANSS positive score, PANSS negative score, PANSS general score, IDS‐C~30~ sum score, YMRS sum score and global assessment of functioning (GAF). In a second step, blockwise logistic regression analyses were performed to estimate the effects of SZ‐PRS for 11 different *p*‐value thresholds, as explained above. Ancestry principal components were calculated specifically for the subsample entering these analyses (for methods see Section [2.2.3](#ajmgb32639-sec-0013){ref-type="sec"}) in order to be able to correct for potential effects of population substructure. The significant phenotypic predictors from the previous analyses, namely sex, sex × age interaction and psychiatric treatment at baseline, as well as the first five ancestry principal components were entered as covariates in the first block. In the second block, the respective z‐standardized SZ‐PRS was added as a predictor. Estimates of change in Nagelkerke\'s *R* ^2^ relative to the SZ‐PRS are reported.

3. RESULTS {#ajmgb32639-sec-0017}
==========

Here, we report data of a total of *N* = 891 clinical individuals that were included in the study at baseline (first study visit; T1). Of these *N* = 891 individuals, 526 (59.0%), 415 (46.6%), and 351 (39.4%) completed the second, third, and fourth study visit, respectively. Importantly, individuals can miss one or more follow‐up study visits without being excluded from the study. In such cases, individuals were re‐contacted again before the next scheduled appointment and invited to continue to participate in the study. Also the numbers above represent a snapshot of the phenotype database taken on the September 19th, 2016. This means that study participants might still be enrolled in the study at that time and complete further study visits.

We compare clinical groups with predominantly affective symptoms (*n* = 367 individuals \[41.2% of total sample\]; 294 with Bipolar‐I Disorder, 68 with Bipolar‐II Disorder, and 5 with reMDD) to those suffering from predominantly psychotic symptoms (*n* = 524 individuals \[58.8% of total sample\]; 424 with SZ, 83 with SZA, 11 with schizophreniform disorder and 6 with brief psychotic disorder). Approximately half of the sample (*n* = 440, 49.8%) was treated as in‐ or daypatient at baseline. Information on recruitment numbers from single study centers is displayed in Supporting Information Table [2](#ajmgb32639-supitem-0002){ref-type="supplementary-material"}.

3.1. Phenotypic analyses {#ajmgb32639-sec-0018}
------------------------

Cross‐sectional comparisons on demographic variables between the two groups are summarized in Table [1](#ajmgb32639-tbl-0001){ref-type="table"}. Participants in the predominantly psychotic group were characterized by a lower proportion of females, a lower age at baseline, a lower age at illness onset, a higher proportion of single (never married) individuals and were more frequently treated as in‐ or daypatients compared to the predominantly affective group. In addition, fewer participants in the predominantly psychotic group reported a family history of psychiatric illness. Descriptive cross‐sectional differences between sexes are summarized in Table [2](#ajmgb32639-tbl-0002){ref-type="table"}. Exemplary, the longitudinal course of acute depressive (IDS‐C~30~) symptoms over the study period is shown in Figure [1](#ajmgb32639-fig-0001){ref-type="fig"}. Analogously, courses of manic (YMRS) and psychotic (PANSS Positive Scale) symptoms as well as psychosocial functioning (GAF) are displayed in Supporting Information Figures [2--4](#ajmgb32639-supitem-0001){ref-type="supplementary-material"}.

###### 

Sex‐specific descriptive statistics of both clinical groups at the first study visit (T1)

                                                   Female          Male
  ------------------------------------------------ --------------- ---------------
  **Affective group**                                              
  *n*                                              178             189
  Age at first visit, mean (range)                 45.2 (21--78)   45.6 (18--76)
  Age at illness onset, mean (range)               33.7 (12--73)   33.5 (11--73)
  Marital status single (never married), *n* (%)   70 (39.5)       88 (47.1)
  Family history of psychiatric illness, *n* (%)   137 (80.6)      131 (75.3)
  In‐ or day patient, *n* (%)                      59 (33.5)       69 (37.5)

  ------------------------------------------------ --------------- ---------------
  *n*                                              210             314
  Age at first visit, mean (range)                 43.8 (19--73)   38.9 (18--72)
  Age at illness onset, mean (range)               29.0 (12--73)   27.1 (7--65)
  Marital status single (never married), *n* (%)   100 (47.8)      236 (75.4)
  Family history of psychiatric illness, *n* (%)   140 (72.5)      194 (65.5)
  In‐ or day patient, *n* (%)                      118 (56.2)      194 (61.8)
  ------------------------------------------------ --------------- ---------------

![Violin plots of the course of depressive symptoms, separately for both patient groups. Individual trajectories are plotted in gray color. The numbers of participants included in this graph (T1--T4, respectively) are: 312, 184, 149, 109 (Affective) and 453, 288, 213, 196 (Psychotic)](AJMG-180-89-g001){#ajmgb32639-fig-0001}

Linear mixed model analyses of depressive symptoms (Table [3](#ajmgb32639-tbl-0003){ref-type="table"}) reveal effects of in‐ or daypatient status at study inclusion (mean IDS‐C~30~ scores at T1‐T4 for in‐ or daypatients: 14.5, 12.2, 13.5, 12.1 and outpatients/no psychiatric treatment: 10.7, 11.3, 9.8, 11.0) and sex (mean IDS‐C~30~ scores at T1--T4 for females: 13.3, 12.2, 12.3, 12.4; males: 12.1, 11.2, 10.2, 10.6). No other variables were significant.

###### 

Longitudinal analysis of depressive symptoms (IDS‐C~30~)

                                      SS      MS      NumDF   DenDF     F       *p*      *p* ~FDR~
  ----------------------------------- ------- ------- ------- --------- ------- -------- -----------
  *Main effects*                                                                         
  Age at first visit                  0.09    0.09    1       823.91    0.21    .648     .729
  In‐ or day patient at first visit   16.81   16.81   1       792.37    38.41   \<.001   \<.001
  Sex                                 2.71    2.71    1       888.67    6.19    .013     .047
  Dx group                            1.52    1.52    1       812.12    3.47    .063     .162
  Time (visit)                        1.72    0.57    3       1295.28   1.31    .269     .372
  *Interaction effects*                                                                  
  Sex × Dx group                      1.11    1.11    1       883.85    2.53    .112     .224
  Sex × time (visit)                  0.76    0.25    3       1308.10   0.58    .630     .729
  Dx group × time (visit)             3.08    1.03    3       1304.03   2.34    .072     .172
  Sex × Dx group × time (visit)       2.04    0.68    3       1307.70   1.55    .199     .325

*R* ^2^ for the model was 5.7%, 95% confidence interval \[4.6, 8.7\]. DenDF = denominator degrees of freedom; Dx = diagnostic; MS = mean square; NumDF = numerator degrees of freedom; *p* ~FDR~ = false discovery rate‐corrected *p*‐value; SS = sum of squares.

Manic symptoms (Table [4](#ajmgb32639-tbl-0004){ref-type="table"}; for post hoc tests see Supporting Information Table [3](#ajmgb32639-supitem-0002){ref-type="supplementary-material"}) were not different between the patient groups after correcting for multiple comparisons (mean YMRS scores at T1--T4: 4.0, 2.5, 2.8, 1.9 \[affective group\] and 2.4, 1.9, 2.3, 2.1 \[psychotic group\]). However, symptoms of mania (Supporting Information Figure [2](#ajmgb32639-supitem-0001){ref-type="supplementary-material"}) differed over time (mean YMRS scores at T1--T4: 3.0, 2.1, 2.5, 2.1), behaved differently in diagnostic groups over time and were independent of in‐ or daypatient status at baseline. Psychotic symptoms (Table [5](#ajmgb32639-tbl-0005){ref-type="table"}; for post hoc tests see Supporting Information Table [4](#ajmgb32639-supitem-0002){ref-type="supplementary-material"}) differed both over time (mean PANSS Positive Scale scores at T1--T4: 12.3, 10.3, 10.4, 10.1) and between diagnostic groups (mean PANSS Positive Scale scores at T1--T4: 9.5, 8.5, 8.6, 8.3 \[affective group\] and 14.2, 11.5, 11.6, 11.1 \[psychotic group\]).

###### 

Longitudinal analysis of manic symptoms (YMRS)

                                  SS      MS     NumDF   DenDF     F      *p*      *p* ~FDR~
  ------------------------------- ------- ------ ------- --------- ------ -------- -----------
  *Main effects*                                                                   
  Age at first visit              0.79    0.79   1       774.58    1.50   .222     .347
  In‐ or day patient at T1        1.11    1.11   1       771.85    2.10   .148     .253
  Sex                             2.39    2.39   1       822.08    4.50   .034     .095
  Dx group                        2.59    2.59   1       748.24    4.88   .028     .083
  Time (visit)                    11.50   3.83   3       1454.76   7.22   \<.001   \<.001
  *Interaction effects*                                                            
  Sex × Dx group                  0.02    0.02   1       814.37    0.03   .856     .856
  Sex × time (visit)              1.63    0.54   3       1471.93   1.03   .380     .489
  Dx group × time (visit)         8.98    2.99   3       1466.84   5.64   .001     .003
  Sex × Dx group × time (visit)   2.84    0.95   3       1471.75   1.79   .148     .253

*R* ^2^ for the model was 2.5%, 95% confidence interval \[0.2, 4.8\]. For abbreviations see Table [4](#ajmgb32639-tbl-0004){ref-type="table"}.

###### 

Longitudinal analysis of psychotic symptoms (PANSS positive score)

                                  SS     MS     NumDF   DenDF     F       *p*      *p* ~FDR~
  ------------------------------- ------ ------ ------- --------- ------- -------- -----------
  *Main effects*                                                                   
  Age at first visit              0.07   0.07   1       848.74    1.24    .267     0.372
  In‐ or day patient at T1        0.57   0.57   1       791.26    10.70   .001     0.004
  Sex                             0.16   0.16   1       923.94    3.04    .082     0.183
  Dx group                        3.46   3.46   1       847.05    65.50   \<.001   \<0.001
  Time (visit)                    6.70   2.23   3       1424.64   42.26   \<.001   \<0.001
  *Interaction effects*                                                            
  Sex × Dx group                  0.07   0.07   1       919.44    1.28    .258     0.372
  Sex × time (visit)              0.16   0.05   3       1437.95   0.99    .398     0.493
  Dx group × time (visit)         0.20   0.07   3       1434.62   1.28    .281     0.375
  Sex × Dx group × time (visit)   0.07   0.02   3       1437.35   0.44    .723     0.766

*R* ^2^ for the model was 14.6%, 95% confidence interval \[12.5, 17.8\]. For abbreviations see Table [4](#ajmgb32639-tbl-0004){ref-type="table"}.

Regarding symptoms, the most prominent difference between both diagnostic groups is the magnitude of psychotic symptoms (Supporting Information Figure [3](#ajmgb32639-supitem-0001){ref-type="supplementary-material"}). In both groups, there is a decrease of impairment after the baseline assessment and toward the end of the study period.

Analyses of GAF values over time (Table [6](#ajmgb32639-tbl-0006){ref-type="table"}; for post hoc tests see Supporting Information Table [5](#ajmgb32639-supitem-0002){ref-type="supplementary-material"}) revealed effects of in‐ or daypatient status, diagnostic group, time and the sex × diagnostic group interaction. Mean GAF values at T1--T4 (Supporting Information Figure [4](#ajmgb32639-supitem-0001){ref-type="supplementary-material"}) were: 61.5, 65.9, 65.1, 64.8 (affective group, females); 61.6, 66.5, 65.5, 66.6 (affective group, males); 54.5, 61.5, 61.6, 60.5 (psychotic group, females); and 52.3, 59.8, 58.8, 56.2 (psychotic group, males).

###### 

Longitudinal analysis of GAF values

                                  SS       MS       NumDF   DenDF     F       *p*      *p* ~FDR~
  ------------------------------- -------- -------- ------- --------- ------- -------- -----------
  *Main effects*                                                                       
  Age at first visit              249.8    249.8    1       861.39    2.86    .091     .193
  In‐ or day patient at T1        6357.0   6357.0   1       215.18    72.83   \<.001   \<.001
  Sex                             207.2    207.2    1       947.67    2.37    .124     .234
  Dx group                        2820.6   2820.6   1       387.57    32.31   \<.001   \<.001
  Time (visit)                    8941.0   2980.3   3       1435.55   34.14   \<.001   \<.001
  *Interaction effects*                                                                
  Sex × Dx group                  466.7    466.7    1       939.32    5.35    .021     .069
  Sex × time (visit)              74.6     24.9     3       1446.20   0.29    .837     .856
  Dx group × time (visit)         203.1    67.7     3       1444.13   0.78    .508     .609
  Sex × Dx group × time (visit)   130.7    43.6     3       1445.69   0.50    .683     .745

*R* ^2^ for the model was 16%, 95% confidence interval \[13.9, 19.3\]. For abbreviations see Table [4](#ajmgb32639-tbl-0004){ref-type="table"}.

3.2. Genetic analyses of population structure {#ajmgb32639-sec-0019}
---------------------------------------------

Supporting Information Figure [5](#ajmgb32639-supitem-0001){ref-type="supplementary-material"} shows the PsyCourse subjects and all 1000 genomes super‐populations based on the first two ancestry principal components and highlights the European origin of most of the subjects of the PsyCourse study.

3.3. SZ‐PRS analyses of the diagnostic group {#ajmgb32639-sec-0020}
--------------------------------------------

A subset of 771 participants with available SZ‐PRS and without missing data in any of the covariates was analyzed. Approximately 57.3% suffered from predominantly psychotic symptoms while 42.7% suffered from predominately affective symptoms. Figure [2](#ajmgb32639-fig-0002){ref-type="fig"} shows changes in Nagelkerke\'s *R* ^2^ due to effects of the SZ‐PRS at 11 different *p*‐value thresholds. Along with the increase of the SZ‐PRS, the odds of being in the predominantly psychotic group increase. The largest effect was observed for the SZ‐PRS at the *p*‐value threshold of .05 (OR = 1.28; 95% CI: 1.10--1.50).

![Effects of SZ‐PRS on diagnostic group. *p*‐Values significant after FDR correction in blue color (baseline model with covariates only: Nagelkerke\'s *R* ^2^ = .091; FDR corrected *p*‐values for the models with *p*‐value thresholds from 5e‐08 to 1: .059, .29, .022, .022, .022, .022, .022, .024, .022, .022, .022)](AJMG-180-89-g002){#ajmgb32639-fig-0002}

3.4. Analyses of follow‐up study participation {#ajmgb32639-sec-0021}
----------------------------------------------

Logistic regression was performed in 498 participants without missing data in the phenotypic predictors, 69.5% of whom had follow‐up data from at least one additional study visit. Detailed results can be found in Supporting Information Table [6](#ajmgb32639-supitem-0002){ref-type="supplementary-material"}. In the baseline model, that is, without any information from phenotypic predictors, 69.5% of the subjects were correctly classified. This rate increased to 73.5% when demographic and disease related variables (for details see Section [2.2.6](#ajmgb32639-sec-0016){ref-type="sec"}) were entered in the regression model. Nagelkerke\'s *R* ^2^ for the model was 0.282. Female sex (*p* = .01; OR = 0.12; 95% CI: 0.02--0.65) and inpatient treatment at baseline (*p* \< .01; OR = 0.32; 95% CI: 0.17--0.60) were significantly associated with decreasing odds of having follow‐up data. The age x sex interaction also had a significant effect in the model (*p* = .049; OR = 1.04; 95% CI: 1.00--1.08). While in both female and male participants older age was associated with increasing odds of having follow‐up data, this age effect was slightly stronger in females.

For the SZ‐PRS analyses, a subsample of 613 subjects with SZ‐PRS and completely available covariates was analyzed, 71.9% of whom had follow‐up data. Figure [3](#ajmgb32639-fig-0003){ref-type="fig"} shows changes in Nagelkerke\'s *R* ^2^ due to effects of the SZ‐PRS at 11 different *p*‐value thresholds. As the SZ‐PRSs increase, the odds of being in the follow‐up group decrease. This trend was significant after FDR correction for risk scores at two different *p*‐value thresholds. Effect sizes at these two *p*‐value thresholds were similar (*p*‐value threshold of 0.0001: OR = 0.79; 95% CI: 0.65--0.95; *p*‐value threshold of .001: OR = 0.78; 95% CI: 0.64--0.95).

![Effects of SZ‐PRS on dropout. *p*‐Values significant after FDR correction in blue color (baseline model with covariates only: Nagelkerke\'s *R* ^2^ = 0.131; FDR corrected *p*‐values for the models with a *p*‐value threshold from 5e‐08 to 1: .705, .03, .03, .088, .115, .15, .175, .175, .175, .175, .175)](AJMG-180-89-g003){#ajmgb32639-fig-0003}

4. DISCUSSION {#ajmgb32639-sec-0022}
=============

Here, we present and provide an initial characterization of the PsyCourse study, a transdiagnostic study of the affective‐to‐psychotic continuum that combines longitudinal deep phenotyping and dimensional assessment of psychopathology with an extensive collection of biomaterial. Broad informed consent by the participants allows this study to serve as a unique future resource for the interrogation of complex genotype--phenotype relationships. The combination of both longitudinal and cross‐sectional phenotype assessments expands the horizon of genetic association studies beyond case--control phenotypes. Data collected in this study will enable researchers to find variants related to disease phenotypes within clinical groups, not confined to traditional diagnostic boundaries, and serve as starting point for the elucidation of disease mechanisms which are urgently needed to develop new therapeutics (see Wendland & Ehlers, [2016](#ajmgb32639-bib-0060){ref-type="ref"} for a review).

4.1. Phenotype analyses of symptom dimensions over time {#ajmgb32639-sec-0023}
-------------------------------------------------------

### 4.1.1. IDS‐C~30~, YMRS, and PANSS positive scores {#ajmgb32639-sec-0024}

Dimensional assessment of depressive, manic, and psychotic symptoms as well as psychosocial functioning were compared between predominantly affective and predominantly psychotic disorders over time to identify hallmarks of the short‐term course of severe mental disorders (Murray et al., [2004](#ajmgb32639-bib-0043){ref-type="ref"}). Our analyses highlight mild depressive symptoms in both clinical groups that do not vary over time or show different patterns over time according to diagnostic group. Overall, females had slightly higher depression scores than men at baseline, an effect also observed in samples containing individuals suffering from either BD (Parker, Fletcher, Paterson, Anderson, & Hong, [2014](#ajmgb32639-bib-0047){ref-type="ref"}) or SZ (Abel, Drake, & Goldstein, [2010](#ajmgb32639-bib-0001){ref-type="ref"}). Psychotic symptoms, the symptom dimension that, predictably, showed the largest difference between diagnostic groups, decreased in both groups after the first study visit. This may be interpreted as common treatment effect, as many clinical participants were treated as in‐ or day patients at the beginning of the study. Manic symptom ratings did not vary between diagnostic groups but showed a different fluctuating pattern over time between predominantly psychotic and predominantly affective groups. Similar to symptoms of depression, symptoms of mania were observed in both diagnostic groups and illustrate symptom overlap between diagnostic groups. The different behavior over time of symptoms of mania in the diagnostic groups is thought to reflect the episodic characteristics of BD (Judd et al., [2002](#ajmgb32639-bib-0031){ref-type="ref"}). The sex effect observed across diagnostic groups in depression scores (higher IDS‐C~30~ scores in females) has neither been reported for SZ (Zisook et al., [1999](#ajmgb32639-bib-0065){ref-type="ref"}) nor BD (Diflorio & Jones, [2010](#ajmgb32639-bib-0019){ref-type="ref"}) and highlights new findings that may emerge when assessing symptom dimensions across diagnostic boundaries.

In summary, both mild depressive symptoms and symptoms of mania were comparable between diagnostic groups, whereas large differences in psychotic symptoms were the primary characteristic separating both diagnostic groups. Furthermore, we highlight a sex‐specific pattern of more severe symptoms of depression in women suffering from severe mental disorders.

### 4.1.2. Effects on psychosocial functioning {#ajmgb32639-sec-0025}

GAF values covary with symptom status by definition, a strong effect of in‐ or day patient status is therefore not surprising and does, of course, not imply causality. In addition, the pronounced difference in GAF values between diagnostic groups may be attributed to a more severe load of psychotic symptoms in the predominantly psychotic group. Analogous to the improvement of psychotic symptoms, we also interpret the GAF improvement over time in both diagnostic subgroups as treatment effect. The finding of a statistical interaction between sex and diagnostic group has been observed before when comparing psychotic and affective illnesses (Gade et al., [2015](#ajmgb32639-bib-0021){ref-type="ref"}; Heilbronner et al., [2016](#ajmgb32639-bib-0027){ref-type="ref"}), reflecting psychotic females to have higher GAF scores than psychotic males, whereas no such sex difference exists in BD.

4.2. SZ‐PRS analyses of diagnostic group {#ajmgb32639-sec-0026}
----------------------------------------

We explored whether SZ‐PRS are able to differentiate between predominantly psychotic versus affective participants in the PsyCourse study. The results are in line with knowledge of not only an overlapping (Purcell et al., [2009](#ajmgb32639-bib-0050){ref-type="ref"}) but also a specific (Ruderfer et al., [2014](#ajmgb32639-bib-0054){ref-type="ref"}) polygenic background of SZ and BD. Nine of 11 SZ‐PRS with different *p*‐value thresholds significantly explained variability of diagnostic group. As expected, a higher SZ‐PRS increased the odds of being in the "predominantly psychotic" group. Across the range of SZ‐PRS, the explained variation is at about 1% toward a *p*‐value threshold of 1. To put that in context, when comparing patients and controls, SZ‐PRS explain about 7% of case--control status in SZ (Ripke et al., [2014](#ajmgb32639-bib-0052){ref-type="ref"}) and about 2% in BD (Charney et al., [2017](#ajmgb32639-bib-0012){ref-type="ref"}; Cross‐Disorder Group of the Psychiatric Genomics Consortium, [2013](#ajmgb32639-bib-0014){ref-type="ref"}; Purcell et al., [2009](#ajmgb32639-bib-0050){ref-type="ref"}). The observation that the amount of explained variability in our analysis is not as high as the effects usually observed when comparing cases and controls is probably due to the common genetic background of the two groups (Purcell et al., [2009](#ajmgb32639-bib-0050){ref-type="ref"}).

4.3. SZ‐PRS analyses of follow‐up participation {#ajmgb32639-sec-0027}
-----------------------------------------------

In the current snapshot of the database, about 70% of the study participants have follow‐up data for at least one study visit during the entire 18 months study period. Gender and the treatment at baseline were associated with dropout. More precisely, being male as well as being treated as an outpatient at baseline increased the odds of having follow‐up data. An effect of age was only significant in interaction with sex. While in both female and male participants older age was associated with increasing odds of having follow‐up data, this age effect was slightly more pronounced in females. Effect sizes of the significant predictors are small and the rate of correctly classified subjects only improved by 4% in comparison to the baseline model. However, the largest effects were observed for in‐ versus outpatient treatment at baseline. The selective dropout of hospitalized, hence more severely impaired, participants must be considered when interpreting longitudinal data from the PsyCourse study.

In the present study, associations between SZ‐PRS and dropout were much lower compared to the findings from Martin et al. ([2016](#ajmgb32639-bib-0041){ref-type="ref"}) in the population‐based Avon Longitudinal Study of Parents and Children (ALSPAC). However, a trend in the expected direction with significant effects for risk scores at two different *p*‐value thresholds was observed. Since the current sample of the PsyCourse study is considerably smaller than the ALSPAC sample with nearly 8,000 subjects, the main reason for the lack of significant findings is presumably lower statistical power. Nevertheless, the results in the present study appear promising and, as recruitment is ongoing, analyses may be repeated using a larger sample in the future. To our knowledge, there is no comparable investigation in a clinical sample yet.

4.4. Limitations of the present study {#ajmgb32639-sec-0028}
-------------------------------------

Here, we present the PsyCourse study and provide an overall characterization of the clinical study sample to illustrate its usefulness in future biological‐psychiatric studies. Therefore, our results are exploratory and should to be treated as such. Furthermore, we did not include medication data in the present analysis. This information will be subject of future studies of the PsyCourse sample. Furthermore, the limited follow‐up period of 18 months should be considered. While a longer period of time would be desirable to study the long‐term course of severe mental illnesses, prospective samples of chronic patients suitable for biological studies on disease course are scarce. While we think that studies on the short‐term course will uncover important mechanisms of severe mental disorders, the PsyCourse study can provide a resource for future longitudinal studies.

4.5. Resource for collaborations {#ajmgb32639-sec-0029}
--------------------------------

The PsyCourse study constitutes a unique resource on different levels. First, the project already created a wealth of phenotypic and biological data, such as genomic, small RNAome, and methylation data. With recruitment still ongoing, the sample size will increase over time. The project constitutes a major contributor to a budding initiative spearheaded by the German Association for Psychiatry and Psychotherapy (DGPPN) with the aim of establishing a prospective national cohort of patients with major psychiatric disorders, the so called "DGPPN cohort" (Anderson‐Schmidt et al., [2013](#ajmgb32639-bib-0004){ref-type="ref"}). While not in the public domain, the PsyCourse study is meant to be available to bona fide researchers all over the world based on mutually agreed memoranda of understanding. The Appendix contains a brief outline of our Data Sharing Policy. Second, the project is accompanied by continuous development of a methodological and logistical framework for longitudinal research in biological‐psychiatry dealing with issues of practical implementation as well as ethical and legal aspects (Schwanke, Rienhoff, Schulze, & Nussbeck, [2013](#ajmgb32639-bib-0056){ref-type="ref"}).
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Participants of the PsyCourse study have consented to us sharing their pseudonymized data with other researchers and research consortia. Thus, PsyCourse data will be made available to bona fide researchers collaborating with us. As we are committed to reproducible research, we are also willing to share data analyzed in this publication with researchers aiming to reproduce our analyses. However, in any case, a mutually agreed written memorandum of understanding must be signed before data can be obtained from us.
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